A two-part study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat oral doses of GSK256073A, in a randomized, single-blind, dose escalation study in healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs GSK 256073 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
- 17 Jul 2007 New trial record.